# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Argus Research analyst David Toung maintains Cardinal Health (NYSE:CAH) with a Buy and raises the price target from $115 to ...
Baltimore secures an $80 million settlement with Teva Pharmaceuticals in its opioid crisis litigation. Funds will be allocated ...
Three major U.S. drug distributors, McKesson, Cencora, and Cardinal Health, have agreed to a $300 million settlement over claim...
JP Morgan analyst Lisa Gill maintains Cardinal Health (NYSE:CAH) with a Neutral and raises the price target from $111 to $123.
Deutsche Bank analyst George Hill maintains Cardinal Health (NYSE:CAH) with a Hold and raises the price target from $115 to ...
UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:CAH) with a Buy and raises the price target from $120 to $125.